Market research
PLX Protalix BioTherapeutics, Inc
AMEX USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 211M
- P/E ratio
- 10.92
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- -0.09
Profile
Instrument facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 211M
- P/E ratio
- 10.92
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- -0.09
About
About Protalix BioTherapeutics, Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
Research context
Protalix BioTherapeutics, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PLX discussion.
5 years, 6 months ago
Protalix BioTherapeutics, Inc is currently in a long term downtrend where the price is trading 55.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.4.
Protalix BioTherapeutics, Inc's total revenue rose by 9.8% to $19M since the same quarter in the previous year.
Its net income has dropped by 97.6% to $7K since the same quarter in the previous year.
Finally, its free cash flow fell by 110.6% to $-8M since the same quarter in the previous year.
Based on the above factors, Protalix BioTherapeutics, Inc gets an overall score of 2/5.